Letter to the Editor:
Repeat Redifferentiation of Radioiodine Refractory BRAF
V600E
Mutated Thyroid Cancer with Dabrafenib
Thyroid
.
2023 Jun;33(6):771-773.
doi: 10.1089/thy.2022.0651.
Epub 2023 May 30.
Authors
Trond Bogsrud
1
2
,
Marita Jacobsen
3
,
Jolanta Durski
4
,
Eivind Larsen
5
,
Ola Engelsen
5
,
Olav Inge Haskjold
6
,
Miguel Castillejo
1
,
Tore Bach-Gansmo
1
,
Douglas Van Nostrand
7
Affiliations
1
PET-Centre, University Hospital of North Norway, Tromso, Norway.
2
PET-Centre, Aarhus University Hospital, Aarhus, Denmark.
3
Department of Oncology, University Hospital of North Norway, Tromso, Norway.
4
Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
5
Department of Medical Physics, University Hospital of North Norway, Tromso, Norway.
6
Department of Radiology, University Hospital of North Norway, Tromso, Norway.
7
Department of Nuclear Medicine, MedStar Washington Hospital Center, Georgetown University Medical Center, Washington, District of Columbia, USA.
PMID:
37212326
DOI:
10.1089/thy.2022.0651
No abstract available
Publication types
Letter
MeSH terms
Humans
Imidazoles
Iodine Radioisotopes*
Mutation
Proto-Oncogene Proteins B-raf / genetics
Thyroid Neoplasms*
Substances
dabrafenib
Iodine Radioisotopes
Proto-Oncogene Proteins B-raf
Imidazoles
BRAF protein, human